Related Experiment Videos
The safety of calcium-channel blockers
1University of California, San Francisco 94121, USA.
Insights
Calcium-channel blockers are safe and effective for hypertension and angina when used appropriately. Recent studies show no increased risk, confirming their role as first-line therapy for selected patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Calcium-channel blockers (CCBs) are widely prescribed for hypertension and angina.
- Concerns exist regarding CCB safety, with some studies linking them to increased myocardial infarction (MI) and death rates.
- Previous safety concerns often stemmed from methodological flaws or the use of short-acting CCBs at high doses.
Purpose of the Study:
- To evaluate the safety and efficacy of calcium-channel blockers in treating cardiovascular conditions.
- To address conflicting findings in existing literature regarding CCB-associated risks.
- To determine the appropriate role of CCBs in current therapeutic guidelines.
Main Methods:
- Review and analysis of existing studies on calcium-channel blockers.
- Examination of methodological quality and patient populations in cited research.
- Comparison of outcomes from short-acting versus long-acting CCB formulations.
- Assessment of confounding factors in observational studies, such as comorbidities and drug dosages.
Main Results:
- Earlier studies suggesting increased MI and death rates were often based on flawed methodologies, old data, or inappropriate use of short-acting CCBs.
- Confounding factors like diabetes and pre-existing heart disease influenced outcomes in some case-control studies.
- More recent, well-controlled studies have not substantiated increased risks when CCBs are appropriately prescribed.
- Short-acting CCBs, particularly nifedipine, showed potential risks when blood pressure was uncontrolled or in specific patient groups.
Conclusions:
- Short-acting calcium-channel blockers have limitations and potential side effects that require careful consideration.
- When appropriately employed in selected patients, calcium-channel blockers do not appear to increase cardiovascular risk.
- Calcium-channel blockers remain a valuable first-line therapy option for hypertension and angina in appropriately selected individuals.
Abstract:
Calcium-channel blockers are widely used as an effective treatment for hypertension and angina. Several studies have raised questions about their safety, suggesting that calcium-channel blockers can increase the rates of myocardial infarction (MI) and death, particularly in patients with heart disease. Reviews of these studies have uncovered serious methodological shortcomings or have found them restricted to short-acting drugs, frequently at high doses or used inappropriately. One study was based on old data regarding only short-acting nifedipine, which has never been indicated for patients who have suffered an MI or unstable angina. A case-control study of short-acting verapamil, diltiazem, and nifedipine suggested an increased MI rate was confounded by the higher rates of diabetes and preexisting heart disease in the patients treated with calcium-channel blockers. A third study reported significantly decreased survival only in patients taking short-acting nifedipine; in most of the cases reported, blood pressure was not controlled. While these studies alert us to the limitations of short-acting calcium-channel blockers and the necessity of considering side effects such as neurohormonal stimulation, a number of more recent, better-controlled studies have not confirmed increased risk with calcium-channel blockers when appropriately employed. Calcium-channel blockers should still be considered first-line therapy in appropriately selected patients with hypertension or angina.